KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBIT Margin (2016 - 2025)

NovoCure's EBIT Margin history spans 12 years, with the latest figure at 23.17% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 1609.0% year-over-year to 23.17%; the TTM value through Dec 2025 reached 23.47%, up 470.0%, while the annual FY2025 figure was 23.47%, 470.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 23.17% at NovoCure, down from 21.54% in the prior quarter.
  • Across five years, EBIT Margin topped out at 0.07% in Q1 2021 and bottomed at 49.71% in Q2 2023.
  • The 5-year median for EBIT Margin is 22.75% (2024), against an average of 24.54%.
  • The largest annual shift saw EBIT Margin plummeted -4872bps in 2023 before it soared 2738bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 17.56% in 2021, then crashed by -91bps to 33.46% in 2022, then dropped by -16bps to 38.66% in 2023, then fell by -2bps to 39.25% in 2024, then surged by 41bps to 23.17% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's EBIT Margin are 23.17% (Q4 2025), 21.54% (Q3 2025), and 24.89% (Q2 2025).